Objective: This study followed remitted patients from a randomized controlled trial of adults with major depressive disorder (MDD). The aims were to describe rates of recurrence and to evaluate 3 clinical predictor domains. Method: Ninety-four treatment-naïve patients (50% female; M age ϭ 38.1 years; 48.9% White; 30.9% Hispanic) with MDD who had remitted to 12-week monotherapy (escitalopram, duloxetine, or cognitive behavior therapy [CBT]) participated in a 21-month maintenance phase (i.e., continued medication or 3 possible CBT booster sessions per year). Recurrence was assessed quarterly, and the clinical predictors were the following: 2 measures of residual depressive symptoms, 1 measure of lifetime depressive episodes, and 2 measures of baseline anxiety. Survival analysis models evaluated recurrence rates, and regression models evaluated the predictors. Results: Among all patients, 15.5% experienced a recurrence, and the survival distributions did not statistically differ among treatments. Residual depressive symptoms on the Hamilton Depression Rating Scale at the end of monotherapy were associated with increased risk for recurrence (hazard ratio ϭ 1.31, 95% confidence interval [CI: 1.02, 1.67], Wald 2 ϭ 4.41, p ϭ .036), and not having a comorbid anxiety disorder diagnosis at study baseline reduced the risk of recurrence (hazard ratio ϭ .31, 95% CI [.10, .94], Wald 2 ϭ 4.28, p ϭ .039).
What is the public health significance of this article?
The results of the current study support the benefits of continued clinical care (i.e., continuation of antidepressant medications or cognitive behavioral therapy booster sessions) for most treatmentnaïve patients who remit to initial monotherapy treatment. However, patients with a comorbid anxiety disorder diagnosis or residual depressive symptoms are at risk for poorer long-term outcomes and may need more specialized forms of initial treatment.
Keywords: cognitive behavioral therapy, antidepressant medication, major depression, recurrence Supplemental materials: http://dx.doi.org/10.1037/ccp0000279.supp Substantial evidence has indicated that antidepressant medications and evidence-based psychotherapies effectively treat depressed individuals (Cuijpers, van Straten, Warmerdam, & Andersson, 2008; Spielmans, Berman, & Usitalo, 2011) . Many such individuals, however, face a significant risk of depressive relapse or recurrence following successful treatment of the acute depressive episode Judd et al., 2016) . Due to the potentially long-term course of major depressive disorder (MDD), clinical guidelines recommend that treatment continue (4 -12 months) beyond the point of initial treatment response (American Psychiatric Association [APA], 2010; National Institute for Health and Clinical Excellence [NICE], 2010) .
Antidepressant medications (ADMs) are the most widely used treatment for MDD (Olfson & Marcus, 2009) , and patients who respond to ADMs and continue to use them appear to have a lower risk of relapse and recurrence than do patients who discontinue medications after a treatment response. A meta-analysis (Geddes et al., 2003) of 31 randomized trials of patients who had responded to ADMs found that those randomized to the continued use of ADMs had a significantly lower risk of relapse than did patients randomized to ADM discontinuation via pill placebo. This differential treatment effect appeared to last up to 36 months, although most of the included trials were limited to 12 months of follow-up. A more recent meta-analysis (Glue, Donovan, Kolluri, & Emir, 2010) reached a similar conclusion, as did an extensive review of maintenance trials published by the U.S. Food and Drug Administration (Borges et al., 2014) .
Cognitive behavioral therapy (CBT), an evidence-based psychotherapy and alternative first-line treatment approach to ADMs, also appears to reduce the risk of relapse and recurrence. An influential meta-analysis (Cuijpers et al., 2013) found that patients initially treated with CBT were less likely to have a relapse than were patients who were successfully treated with ADMs and then withdrawn from treatment. Cuijpers et al. (2013) also reported there was no difference in outcomes between those patients who responded to initial CBT and those patients who responded to initial ADMs and continued to use them during the follow-up.
Despite these promising data on the long-term efficacy of maintenance ADMs and CBT, most treatment studies ended their follow-up period after 1 year (Borges et al., 2014; Cuijpers et al., 2013; Geddes et al., 2003; Glue et al., 2010) . This is problematic because the cumulative risk of recurrence increases beyond 1 year after treatment (Solomon et al., 2000) , and practice guidelines recommend that clinicians make treatment decisions that could last beyond 1 year (APA, 2010; NICE, 2010) . Further, because of appropriate a priori research design reasons, the few studies that have directly compared the long-term efficacy of CBT and continuation ADMs for longer than 1 year of follow-up have, at the end of 1 year of treatment, withdrawn continuation ADM patients from treatment rather than maintaining them on the effective ADM (e.g., Dobson et al., 2008; Hollon et al., 2005) . Consequently, during the second year of follow-up these studies have used naturalistic designs, which involve fewer clinical contact hours and potentially limited treatment efficacy. Thus, there is a need for a study that allows patients to continue using ADMs through a second year of controlled clinical care and permits comparison to the long-term efficacy of CBT.
The present study addressed the preceding limitations with data from the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study (Dunlop, Binder, et al., 2012; Dunlop et al., 2017) . The PReDICT project was a multistage randomized controlled trial for the treatment of MDD in adults. The current analyses include those patients who remitted to 12-week monotherapy (ADMs or CBT) and then participated in a 21-month follow-up during which they could continue treatment; ADM participants could continue to use medication, and CBT participants could receive up to three CBT booster sessions per year. The primary aim of the present study was to describe the rates of recurrence among these patients. Based on the highly controlled nature of the study protocol and the inclusion of only patients who experienced the optimal initial treatment outcome (i.e., remission), it was expected that rates of recurrence would be lower than reported in previous studies. In addition, it was expected that CBT with occasional booster sessions would have long-term efficacy that was comparable to continuous treatment with ADMs.
Secondary Aim
Leading treatment guidelines recommend that clinicians assess a patient's risk of relapse and recurrence at the end of initial and continuation treatment (APA, 2010; NICE, 2010) . To improve the assessment of patient risk, clinicians need to know which clinical variables reliably predict relapse and recurrence. Three such variables derived from prior relevant studies are: (a) number of lifetime depressive episodes at baseline; (b) baseline comorbid anxiety; and (c) residual, subthreshold depression symptoms. These variables are cited as predictors of risk in the treatment guidelines This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. (APA, 2010; NICE, 2010) and have also been cited in reviews of cross-sectional and longitudinal community studies (Burcusa & Iacono, 2007) and clinical cohort studies Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010) . The secondary aim examined clinical variables that might predict MDD recurrence across treatment modalities. Specifically, it was hypothesized that residual symptoms, number of lifetime depressive episodes, and comorbid baseline anxiety would differentiate patients who experienced a recurrence from those who did not.
Method

Study Overview
PReDICT was a randomized controlled trial aimed at identifying moderators of treatment response among patients who had never previously received treatment for MDD. The study rationale, methods, and design have been described in detail elsewhere (for study protocol see Dunlop, Binder, et al., 2012) . In brief, patients were randomized 1:1:1 to one of three 12-week monotherapies: 
Participants
The present study included the PReDICT patients who remitted to 12-week monotherapy with no major protocol violations (n ϭ 109) and agreed to participate in the 21-month follow-up (n ϭ 94). Monotherapy remission was defined as a 17-item Hamilton Depression Rating Scale (HAM-D; Hamilton, 1967) score of Յ7 at both Weeks 10 and 12 of monotherapy treatment. Outcomes from the 12-week monotherapy phase have been described in detail in an earlier report (Dunlop et al., 2017) . All participants were assessed and treated under one umbrella clinic located at a university-affiliated outpatient setting and a Spanish-speaking outpatient setting in a large public hospital (Aponte-Rivera et al., 2014) . Site was not associated with recurrence, so the data from both sites were combined in the currently reported analyses.
Procedure
Participants were assessed every 3 months during the 21-month follow-up. These assessment visits consisted of a Longitudinal Interval Follow-up Evaluation (LIFE; Keller et al., 1987) interview and clinical ratings on the HAM-D (Hamilton, 1967) and Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959) by a masked rater, a clinical interview with a psychiatrist, and several selfreport measures. Patients continued participating in follow-up until one of the following points: (a) 2 years from study baseline, (b) depressive recurrence, or (c) early termination or lost to follow-up. Participating patients received $50 per follow-up visit.
Patients who remitted to ADM and agreed to participate in follow-up (ESC, n ϭ 34; DUL, n ϭ 37) were encouraged to remain on medication through the first 9 months of follow-up, at which point a study psychiatrist discussed the risks and benefits of discontinuing medication. Patients could choose to maintain or stop medications, and patients remained in the follow-up protocol for 12 additional months regardless of their choice. Of the 58 ADM patients who did not leave the study or suffer a recurrence before or at the 9-month follow-up visit (12 months after PReDICT baseline assessment), 17 (29.3%) had stopped their ADM; these patients continued to participate in all remaining follow-up assessments until recurrence, early termination, or the end of the study.
Patients who remitted to CBT monotherapy and agreed to participate in follow-up (n ϭ 23) were offered up to three booster sessions during the first 9 months of follow-up and up to three additional booster sessions during the second year of follow-up. All booster sessions were separated by at least 1 month, and an additional "crisis session" was also allowed for patients during each year of follow-up.
Measures
Depression severity and recurrence. The LIFE (Keller et al., 1987 ) is a semistructured interview that tracks the exact dates of the onset and remission of psychiatric disorders, including MDD recurrence and time survived until recurrence. The LIFE has demonstrated high interrater reliability for episodic disorders (intraclass correlation ϭ .90, Keller et al., 1987) . The LIFE interview was conducted at the end of 12-week monotherapy treatment and at each of the seven quarterly visits during the 21-month followup. The 17-item HAM-D (Hamilton, 1967; Williams, 1988 ) is a clinician-rated measure of depressive symptom severity over the past week and is one of the more commonly used measures in psychotherapy and antidepressant medication research. Patients were rated on the HAM-D throughout monotherapy treatment and at each follow-up visit.
Definition of recurrence. The present study followed the guidelines of other investigators (e.g., Jarrett, Minhajuddin, Gershenfeld, Friedman, & Thase, 2013) in referring to relapse and recurrence as the single construct labeled recurrence. The a priori definitions of recurrence used in PReDICT included a patient's meeting any one of the four following criteria: (a) meeting criteria for a major depressive episode (MDE) based on a LIFE score of 3 or greater; (b) a 17-item HAM-D Ն14 for two consecutive weeks (patients with a HAM-D Ն14 at a follow-up visit were asked to return the following week for an additional rating); (c) a 17-item HAM-D Ն14 at any follow-up visit and at which time the patient requested an immediate change in treatment; and (d) high risk of suicide, as determined by the study psychiatrist (Dunlop, Binder, et al., 2012) .
Residual symptoms. Residual symptoms were operationalized as the patient's 17-item HAM-D total score at the end of the initial 12-week treatment. Residual symptoms were also measured by patients' total score on the self-report Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) at the end of the initial 12-week treatment.
Lifetime depressive episodes. The number of episodes was based on data collected at PReDICT baseline via the Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Gibbon, & Williams, 1995) . Patients were categorized into two groups: patients with less than three lifetime depressive episodes (including the current MDE), and patients with three or more lifetime epiThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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sodes. This cutoff was selected because there is evidence that MDD becomes a chronic, recurrent disorder after three lifetime episodes (Solomon et al., 2000) , and this dichotomous classification has been employed in many studies of recurrence of major depression Kuyken et al., 2016; Stangier et al., 2013) . Anxiety. Anxiety was operationalized as a patient's anxiety disorder status (i.e., no vs. yes) as determined by the PReDICT baseline SCID. Clinician ratings of patient anxiety severity on the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959) at PReDICT baseline were used as an additional measure of anxiety.
Data Analyses
The following series of preliminary comparisons were performed using chi-square tests and analysis of variance on the seven demographic and 11 clinical variables listed in Table 1 . First, eligible patients who agreed to participate in the present study were compared to eligible patients who did not agree to participate, and those patients who did not agree to participate were also compared across treatment groups. Second, to evaluate risk of differential retention of patients from the monotherapy phase to follow-up phase, we compared treatment groups at the beginning of the present study. Because differential retention of participants can affect group equivalence created by initial randomization (e.g., Klein, 1996) , conservative probability values (p Ͻ .10) were used for the treatment group comparisons per the method used in similar trials (e.g., Dobson et al., 2008; Hollon et al., 2005) . Third, patients who terminated the study early (prior to the end of the 21-month follow-up) were compared to all other participating patients (i.e., those who completed the 21-month follow-up and those who CBT (n ϭ 23) ESC (n ϭ 34) DUL (n ϭ 37) This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
suffered a recurrence and were subsequently withdrawn from the study). In addition, patients who terminated the study early were compared across treatment groups. For the primary analyses, survival curves and times were estimated using the Kaplan-Meier product limit method (Kaplan & Meier, 1958) , and the Mantel-Cox test was used to evaluate differences across treatments (Mantel, 1966) . The clinical predictor variables were evaluated using the Kaplan-Meier and MantelCox methods for categorical variables and the Cox proportional hazard regression model (Cox & Oakes, 1984) for continuous variables. In addition, Cox regressions were used to generate effect sizes (i.e., hazard ratios). Patient end points were defined as recurrence; patients lost to follow-up were right-censored at the date of their final study visit, and patients who completed the entire follow-up protocol without recurrence were right-censored at 21 months after the end of monotherapy.
All analyses were conducted at a statistical significance of p Ͻ .05, unless otherwise noted, and SPSS 24.0 was used for the analyses. For all analyses including categorical variables, Fisher's exact test was substituted in analyses with small cells. Additionally, for some analyses, treatment conditions were collapsed to increase statistical power.
Results
Patient Flow and Attrition
One hundred nine patients remitted to 12-week monotherapy without any major protocol violations and were eligible to participate in the present study. Fifteen of these patients did not participate in follow-up. Specifically, seven patients were not offered follow-up because that aspect of the study had not been initiated by the time they completed monotherapy; two patients refused to participate; and six patients consented but never returned for a follow-up evaluation. When compared to patients who agreed to participate (n ϭ 94), these 15 nonparticipating patients were older (M age ϭ 43.9 vs. 38.1) and more likely to identify as White. When the seven patients who were not offered follow-up were excluded, the previous differences were no longer significant. Participation rates, excluding the seven patients who were not offered followup, did not differ significantly across treatments: ESC, 100% (34/34); DUL, 90.2% (37/41); and CBT, 85.2% (23/27; Fisher's exact test, p ϭ .055).
When evaluating the primary sample for this study, that is, the 94 patients who agreed to participate, the treatment groups did not differ on any of seven demographic or 11 clinical variables (see Table 1 ). Of the participating patients, 21 (22.3%) left the study before suffering a recurrence or completing the entire 21-month follow-up protocol; the lost to follow-up rates did not differ among treatments: ESC, 29.4% (10/34); DUL, 24.3% (9/37); and CBT, 8.7% (2/23), 2 (2, N ϭ 94) ϭ 3.53, p ϭ .17. The complete participant flow is summarized in Figure 1 , and the sample characteristics are reported in Table 1 .
Prevention of Recurrence
Only 13 patients suffered a recurrence 1 (ns ϭ 3, 5, and 5 for ESC, DUL, and CBT, respectively), and the survival curves for the entire 21-month follow-up period are presented in Figure 2 . The Kaplan-Meier estimated rate of recurrence across all treatment conditions during this period was 15.5%, and estimated rates of recurrence for the treatment groups were as follows: ESC, 10.6%; DUL, 15.7%; and CBT, 22.4%. The survival distributions did not statistically differ across treatment conditions, Mantel-Cox 2 (2) ϭ 1.74, p ϭ .42, when the ADM conditions were collapsed into one group and compared with the CBT condition (estimated recurrence rates: 13.3% vs. 22.4%), (1) ϭ 1.46, p ϭ .23, or in any of the pairwise comparisons.
Due to the numerically higher lost to follow-up rates in the ADM treatment arm, a series of sensitivity analyses (Shih, 2002) were completed and are described in the online supplemental materials. Across all analyses, the estimated combined rate of recurrence across treatment conditions ranged from 17.7% to 21.0%, and the estimated ranges in rates of recurrence for the treatment conditions were as follows: ESC, 13.7%-20.3%; DUL, 18.0%-18.4%; and CBT, 22.4%-27.0%. None of these analyses identified statistically significant differences.
Treatment Utilization
Seventy percent (50/71) of ADM patients continued to use medications as prescribed and monitored by the study psychiatrist until the end of their study participation (i.e., recurrence, early termination, or study termination). Rates of recurrence did not statistically differ between patients who discontinued medication and patients who continued medications; the observed recurrence rates were as follows: discontinued ADMs, 14.3% (3/21), vs. continued ADMs, 10.0% (5/50; Fisher's exact test, p ϭ .686). All participating CBT patients (23/23) attended at least one booster session, and the number of booster sessions attended, adjusted for survival time, was not significantly associated with recurrence. Five of the 23 (21.7%) CBT patients utilized a crisis session, and two of the five (40%) who attended a crisis session experienced a recurrence compared to three of 18 (16.7%) who did not attend a crisis session; the small numbers precluded statistical analyses.
Prediction of Recurrence
Residual depressive symptoms on the HAM-D following monotherapy were evaluated via a Cox regression model; the analysis revealed that higher levels of residual symptoms were associated with an increased risk in recurrence and decreased survival time (hazard ratio ϭ 1.31, 95% confidence interval [CI: 1.02, 1.67], Wald 2 ϭ 4.41, p ϭ .036). Self-reported residual symptoms on the BDI, however, were not significantly associated with recurrence (hazard ratio ϭ 1.07, 95% CI [.89, 1.30], Wald 2 ϭ .53, p ϭ .468).
Based on number of lifetime MDEs, patients were categorized into two groups: patients with less than three episodes and patients 1 An analysis also evaluated patients who suffered a relapse, defined as meeting the aforementioned recurrence criteria at or before the 6-month follow-up visit (i.e., 9 months from the original Predictors of Remission in Depression to Individual and Combined Treatments study baseline). Only three patients relapsed during this time period (one in each treatment condition), and the Kaplan-Meier estimate of the relapse rate across all treatment conditions was 3.2%. The estimated rates of relapse for the treatment groups were as follows: escitalopram: 3.1%, duloxetine: 2.7%, and cognitive behavioral therapy: 4.3%, and the survival distributions did not statistically differ across any of the comparisons. This document is copyrighted by the American Psychological Association or one of its allied publishers.
with three or more episodes. The observed recurrence rate for patients with fewer than three episodes was 11.9% (8/67), and the observed rate among patients with three or more episodes was 18.5% (5/27). The Kaplan-Meier estimated survival distributions did not statistically differ between groups, Mantel-Cox 2 (1) ϭ .69, p ϭ .408, and having fewer than three lifetime depressive episodes was not significantly associated with a lower risk of recurrence compared to those who had three or more episodes (hazard ratio ϭ .63, 95% CI [.21, 1.92], Wald 2 ϭ .67, p ϭ .412). Patients were divided into two groups based on anxiety disorder status (i.e., no vs. yes) at PReDICT baseline. The observed recurrence rate for patients without an anxiety disorder at study baseline was 7.9% (5/63), and the observed rate among patients with an anxiety disorder was 25.8% (8/31). The Kaplan-Meier survival distributions were significantly different between the two groups, (1) ϭ 4.80, p ϭ .029; not having an anxiety disorder at study baseline was associated with decreased risk of recurrence and longer survival times (hazard ratio ϭ .31, 95% CI [.10, .94 An additional model was constructed to evaluate whether HAM-D residual symptoms mediated the relationship between baseline anxiety disorder diagnosis and recurrence. The indirect effect of baseline anxiety disorder diagnosis through HAM-D residual symptoms was not statistically significant (p ϭ .49), and the direct effect of anxiety diagnosis, controlling for residual symptoms, was statistically significant (p ϭ .03).
Power Considerations
Ninety-four patients participated in the present study (ns ϭ 34, 37, and 23 for ESC, DUL, and CBT, respectively), and 60 patients (ns ϭ 21, 23, and 16 for ESC, DUL, and CBT, respectively) completed the entire 21-month follow-up protocol. Sensitivity analyses revealed that, depending on the comparison and frequency of participant attrition, the study was adequately powered to detect approximately .30 -.50 differences in recurrence rates (e.g., a recurrence rate of 10% in ESC compared to a rate of 40% in DUL).
Discussion
The current results indicated that patients who remitted to their first evidence-based treatment for MDD and who continued to receive This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
maintenance treatment had a low risk of MDD recurrence. The overall recurrence rate of 15.5% was lower than the rates reported for patients followed naturalistically (e.g., Solomon et al., 2000) and for patients who responded to initial ADM treatment and then switched to placebo (Borges et al., 2014; Geddes et al., 2003; Glue et al., 2010) . Moreover, the recurrence rates in the current study were lower than rates reported in other large-scale trials with ADM and CBT (Dobson et al., 2008; Hollon et al., 2005; Jarrett et al., 2013; Shea et al., 1992) . One potential explanation for the low rates of recurrence in the current study is that most prior research followed patients who had responded to initial treatment, whereas the current study followed only patients who had remitted. Given the documented positive relationship between the number of residual symptoms and relapse and recurrence (Judd et al., 1998; Paykel et al., 1995) , it is reasonable to expect higher rates of recurrence among responders compared to remitted patients because nonremitting responders, by definition, have more residual symptoms at the end of treatment. Indeed, fully remitted patients have better long-term outcomes than do patients who do not achieve full remission . Another potential explanation is that the PReDICT study excluded patients who had received prior treatment. Patients with a history of failed treatment and patients who have previously Note. CI ϭ confidence interval; HAM-D ϭ 17-item Hamilton Depression Rating Scale; BDI ϭ Beck Depression Inventory; MDEs ϭ lifetime major depressive episodes; HAM-A ϭ Hamilton Anxiety Rating Scale. This document is copyrighted by the American Psychological Association or one of its allied publishers.
responded to treatment but subsequently relapsed or suffered a recurrence may possess characteristics that make them vulnerable to recurrent depressive episodes; both sets of circumstances have resulted in attenuated treatment outcomes . The similar low recurrence rate among the patients who continued (10%) versus those who discontinued (14.3%) their medication during the follow-up period is particularly notable. In the database of Food and Drug Administration-registered doubleblind antidepressant discontinuation trials evaluating 6 -12 months of maintenance treatment, recurrence rates among patients continuing on antidepressants versus those who discontinued them varied widely: 2%-39% (M ϭ 18%) vs. 14%-59% (M ϭ 37%), respectively (Borges et al., 2014) . Thus, the recurrence rate with continued medication in the current analysis is similar to that in prior studies, but the rate after discontinuation is substantially lower. This low rate of recurrence among patients stopping their antidepressant may stem from (a) the longer total period of medication treatment prior to its discontinuation in the PReDICT sample (M ϭ 46 weeks), (b) the low level of residual depressive symptoms due to all included patients' having achieved remission during the acute treatment phase, or (c) the study sample's being treatment-naïve and therefore less vulnerable to potential tolerance effects of antidepressant medications (Fava & Offidani, 2011) .
The results from the current study show that controlled and sustained clinical care can reduce patient risk of recurrence for as long as 21 months of follow-up. This finding is important because the majority of treatment studies have followed patients for 1 year or less (Borges et al., 2014; Cuijpers et al., 2013; Geddes et al., 2003; Glue et al., 2010) . Moreover, this finding provides guidance for clinicians who must frequently make decisions about treatment that may extend beyond 1 year after initial treatment began (APA, 2010; NICE, 2010) .
In terms of relative treatment efficacy, the three conditions produced similar low rates of recurrence; there were no statistically significant differences across conditions. This result is consistent with arguments for the comparable efficacy of initial CBT versus acute ADMs plus continued ADMs (Cuijpers et al., 2013; Hollon, Stewart, & Strunk, 2006) .
The current study also found that residual symptoms on the HAM-D predicted recurrence. This finding is consistent with the aforementioned evidence for residual symptoms' predicting relapse and recurrence (Judd et al., 1998; Paykel et al., 1995) and with STAR ‫ء‬ D findings that residual symptoms predicted relapse among remitters to initial treatment (Nierenberg et al., 2010) . Residual symptoms may predict relapse and recurrence because they indicate that patients are still suffering somewhat from the index depressive episode, making them more vulnerable to another depressive episode (Judd et al., 2016) . This finding has important implications for treatment because many patients end initial treatment with residual symptoms Dimidjian et al., 2006; Dunlop et al., 2017; Elkin et al., 1989; Keller et al., 2000) . Moreover, evidence that residual symptoms predict recurrence even among remitters has supported recent efforts to define more stringent MDD outcome criteria (Dunlop, Holland, Bao, Ninan, & Keller, 2012; Judd et al., 2016) .
The current study also found that an anxiety disorder diagnosis at study baseline predicted recurrence. This is consistent with evidence from longitudinal studies that have also found a relationship between anxiety disorder diagnoses and MDD recurrence (Coryell, Endicott, & Keller, 1991; Rao, Hammen, & Daley, 1999; Wilhelm, Parker, Dewhurst-Savellis, & Asghari, 1999) . Patients with a comorbid anxiety disorder may suffer from greater exposure to an underlying vulnerability factor for recurrence than do patients without comorbid anxiety. For example, these patients may rely on emotion-regulation strategies like rumination and avoidance that put them at risk for emotional disorders (Barlow, Allen, & Choate, 2004; Hayes, Wilson, Gifford, Follette, & Strosahl, 1996) . This finding is clinically relevant because of the significant comorbidity of depression and anxiety (Kessler et al., 2005; Trivedi et al., 2006) . It also suggests the need for modified treatments that differentially target factors that maintain anxiety and depression.
Even though anxiety disorder diagnoses at study baseline predicted recurrence in the current study, baseline anxiety symptom severity on the HAM-A did not. This differs from results from a recent study that found that anxiety symptom severity predicted relapse in the CBT condition and that an anxiety disorder diagnosis did not predict relapse in any of the treatment conditions (Forand & DeRubeis, 2013) . Moreover, there is evidence that anxiety symptom severity predicts duration of depressive symptoms over and above residual depressive symptoms (Coryell et al., 2012) . One potential explanation for the results in the current study is the use of the HAM-A as a measure of anxiety symptoms. Studies that have found a relationship between anxiety symptoms and subsequent depression symptoms have generally used other measures (Coryell et al., 2012; Forand & DeRubeis, 2013) . In addition, the HAM-A has been criticized for tapping aspects of depression and missing aspects of anxiety (Koerner, Antony, & Dugas, 2010; Maier, Buller, Philipp, & Heuser, 1988) . Despite these discrepancies in the literature, there has been accumulating evidence that comorbid anxiety likely impacts acute and maintenance depression treatment outcomes and there may be a need for more specialized treatments tailored for unique pathological pathways or constructs underlying specific subtypes of comorbid anxiety and depression.
Finally, the current study did not find that patients with three or more lifetime depressive episodes had a greater risk of recurrence than did patients with two or fewer lifetime episodes. Numerous studies have found that patients with more lifetime depressive episodes are at increased risk of recurrence (e.g., Bulloch, Williams, Lavorato, & Patten, 2014; Mueller et al., 1999) , and lifetime MDEs have been found to moderate treatment outcomes to psychotherapies that specifically target the prevention of MDD relapse and recurrence (e.g., Bockting et al., 2005; Teasdale et al., 2000) . Given these discrepancies, it is possible that the current study may not have been sufficiently powered to detect the difference in risk between the two groups. A more plausible interpretation, however, is that participants in the current sample were treatment-naïve, for whom the number of lifetime episodes may have a weaker predictive value for recurrence than has the degree of success of their initial treatment.
There are several limitations of the current study. First, a key limitation of any follow-up study is the risk of differential retention of patients (Klein, 1996) . For the current study, less than 30% of all patients initially randomized to treatment were eligible (i.e., remitted to monotherapy) and actually participated in follow-up. Although analyses did not detect differences in participants across treatment groups at the start of follow-up, differing lost to This document is copyrighted by the American Psychological Association or one of its allied publishers.
follow-up rates could have biased treatment comparisons. However, lost to follow-up rates in the current study were comparable to those observed in similar studies, and sensitivity analyses did not find that early termination affected the study results. Second, although the sample size in the current study was comparable to that of similar trials, the current study in some instances lacked statistical power to detect small to moderate, yet potentially clinically significant, effects between treatments conditions. Third, the study sample was treatment-naïve, which may limit the study's generalizability to individuals who are depressed and have failed prior treatments. It is worth noting, however, that remission rates from the monotherapy phase of the PReDICT study were only slightly higher when compared to those of other depression treatment studies (Dunlop et al., 2017) , suggesting that treatment efficacy may be comparable between treatment-naïve and non-naïve patients. Fourth, patients could choose to end continuation treatment during follow-up, which might have introduced unsystematic change into the study, though most patients continued treatment throughout follow-up.
The current study found low rates of recurrence among patients who remitted to monotherapy and received systematic evaluation and treatment for up to 2 years. It provides much-needed long-term follow-up information regarding the comparable efficacy of CBT and ADMs and supports recommendations to make full remission the target of initial treatment (Keller, 2003) . The results for recurrence rates support the benefits of continued clinical care (i.e., continuation ADMs or CBT booster sessions) for most patients who remit to initial monotherapy treatment. Nevertheless, remitted patients with a comorbid anxiety disorder diagnosis at the beginning of treatment and those with residual depressive symptoms after initial treatment are at risk for poorer long-term outcomes despite achieving remission.
